Systemic Glucocorticoid Treatment for Cutaneous Rosai-Dorfman Disease Affecting the Left Ear: A Case Study - Takeaways - MDSpire

Systemic Glucocorticoid Treatment for Cutaneous Rosai-Dorfman Disease Affecting the Left Ear: A Case Study

  • By

  • Xiaoxue Zhuo

  • Zhuoma Dangzeng

  • Peiyu Zhou

  • Tingting Wang

  • Lin Wang

  • April 21, 2026

  • 0 min

Share

  • 1

    A 49-year-old man diagnosed with cutaneous Rosai-Dorfman disease presented with facial nodules and hearing loss.

  • 2

    Histopathological analysis confirmed the diagnosis, showing S100-positive histiocyte-like cells and emperipolesis.

  • 3

    Initial treatment with prednisone and methotrexate was ineffective, leading to the discontinuation of methotrexate.

  • 4

    Monotherapy with prednisone resulted in gradual resolution of skin lesions and improvement in hearing after two months.

  • 5

    The patient remained asymptomatic with stable hearing and no relapse during a 7-month follow-up.

Original Source(s)

Systemic Glucocorticoid Treatment for Cutaneous Rosai-Dorfman Disease Affecting the Left Ear: A Case Study

  • by Xiaoxue Zhuo, Zhuoma Dangzeng, Peiyu Zhou, Tingting Wang, Lin Wang

  • April 21, 2026

Related Content

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Side Effects: The Details Hiding in Plain Sight

Phones in class, a 25-year prescription gone wrong, pickleball's hidden danger, and why your spin class is too loud — four findings hiding in everyday care.

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.